랩지노믹스

Business Overview

Founded in 2002 and listed on KOSDAQ in 2014, LabGenomics is a natural science and engineering R&D company whose core businesses are in vitro diagnostics (IVD) service and product development and NGS (next-generation sequencing)-based genetic testing. In Korea, it provides outsourced specimen testing services including molecular diagnostics covered by national health insurance, and in the United States it provides local diagnostic services through CLIA labs (Clinical Laboratory Improvement Amendments-certified labs) it has acquired (Business Report).

The company's U.S. entry began in 2023-07/08 with the acquisition of New Jersey-based QDx (approximately 768억원), followed in 2024-09 by the acquisition of three additional CLIA labs under IMD — in New Jersey, Sacramento, Aurora, and Berkeley — for approximately 130억원, securing nationwide U.S. coverage through a total of four CLIA labs (Pharm Edaily, Hit News). Since 2026, the company has pursued a strategy of consolidating pathology, gastroenterology, and cancer diagnostics under the single 'LabGenomics' brand, and on 2026-08-04 it was reported that a national sales meeting attended by sales staff from 27 U.S. states was held at its New Jersey laboratory, doubling the sales organization and newly appointing Tim Murray — with 20 years of experience in U.S. diagnostic testing sales — as Vice President of Sales (Newspim, 2026-08-04).

As new business initiatives, the company signed a business agreement with Fitpet to develop liquid-biopsy-based companion animal tumor biomarkers (MediToday), and is pursuing the development and commercialization of a respiratory LDT (Laboratory Developed Test) diagnostic kit aimed at cost reduction. Performance surged in 2020-2021 due to COVID-19 diagnostic kit demand, but as the revenue base contracted after the pandemic became endemic, the company has been shifting its growth axis toward its U.S. CLIA lab acquisitions (Business Report).

Revenue breakdown by business segment (specimen testing, NGS, U.S. CLIA labs) and the domestic/overseas revenue split are not available (require direct review of official IR materials and the original Business Report).

Recent News Flow

• 2026-08-04: The KOSDAQ index as a whole surged sharply enough to trigger an intraday sidecar (KOSDAQ 150 futures +6.09%); LabGenomics' rise coincided with this broad market strength (Newspim).
• 2026-08-04: It was reported that a national sales meeting was held at the company's New Jersey laboratory in the U.S., consolidating two CLIA labs under a single brand and doubling the sales organization (Newspim).
• 2026-07-09: Amid mixed performance among top-traded KOSDAQ stocks by value, LabGenomics surged sharply; the exact percentage change is reported differently across media outlets (Seoul Shinmun).
• 2026-06-15: Alongside news of an on-market share purchase (approximately 20억원) by the largest shareholder group on 6/12, there was a report that a company official stated the view that 'the current share price is undervalued relative to intrinsic value' (this is a personal statement by the official, not a factual determination, Newspim).
• 2026-06-09: The share price rose alongside news of a 200억원 convertible bond investment by STIC Investments, with the percentage change reported differently across media outlets (Ajou Kyungjae, Nate News).
• 2026-04-16: The share price rose +16.53% to close at 1,523원 on news of the spread of a new COVID-19 variant (BA.3.2) (Biotimes).

No primary disclosure or individual news article directly explaining the 2026-08-04 surge was found within the search scope (not available).

Financial Trends

Annual 2022 results and the year-by-year time series for total liabilities, total equity, and the cash flow statement are not available.

Valuation (Factual Multiples)

On a recalculated basis, PBR is approximately 0.373배, below the 5-year average PBR of 1.19배 (Value Line; note that reference dates differ). Forward PER/PBR (consensus) is not available due to the absence of analyst coverage.

Peer Comparison

The industry is divided into two consortia: a five-company group comprising EDGC, Clinomics, Medigene Human Care, LabGenomics, and CancerRop, and a three-company group comprising TheragenBio, DNA Link, and Macrogen (KPGP). In the H1 2025 performance comparison, only LabGenomics recorded revenue growth, while the other three companies saw profitability deteriorate (Dealsite).

Investor Flows

Flow window: 2026-07-04 to 2026-08-04 (21 trading days), source: pykrx (KRX login successful; totals and reference dates were not cross-checked against the official KRX site — treated as estimates). On a 1-month cumulative basis: foreign -5.96억원, institutional +9.78억원, individual -4.35억원. Daily short-selling ratio (%), foreign ownership limit utilization rate, and margin loan balance are not available.

Governance and Capital Raising

On 2026-05-12, the Board of Directors resolved to issue the 5th unregistered, unsecured, privately placed convertible bonds (200억원). The coupon rate is 0.0%, the yield to maturity is 5.0%, the maturity date is 2029-05-20, and the conversion price is 1,466원 (convertible into 13,642,564주, 18.38% of total shares outstanding), with the conversion request period running 2027-05-20 to 2029-04-20. It was confirmed via a new large-shareholding report filed on 2026-05-28 that STIC Litmus LLC acquired this CB (DART).

The combined stake of the largest shareholder group (Ruha Private Equity · Ruha Galacticos) and its special related parties decreased from 30.93% on 2024-08-20 to 24.21% on 2026-05-26, and subsequently increased again through disclosed on-market purchases (DART Report on Large Holdings of Stocks, Etc.).

On 2026-06-29, the Board of Directors resolved a 5:1 reverse stock split changing the par value per share from 500원 to 2,500원 (total shares outstanding to change from 74,239,990주 to 14,847,998주). An extraordinary general meeting of shareholders is scheduled for 2026-08-18; if approved, the trading suspension period will run 2026-09-01 to 09-22, with the new shares scheduled to list on 2026-09-23. The original disclosure states that this does not constitute a capital reduction (DART).

On 2026-05-20, Research Institute Director (Managing Director) Oh Mi-jin disposed of 28,968주 of common shares (49.0% of her existing holdings) on the market at 1,455원 per share (elestock report, DART).

Macro Environment

The 'Health Insurance Fee Structure Reform Plan' announced by the Ministry of Health and Welfare on 2026-06-25 includes lowering the average overcompensation level for specimen testing from 190% to 150% and abolishing the outsourced-testing management fee (10%), with Phase 1 implementation scheduled for H2 2026. This has been confirmed as a factual matter that could exert downward pressure on the unit prices of LabGenomics' core revenue source — domestic outsourced molecular diagnostics and genetic testing (Ministry of Health and Welfare).

LabGenomics imports NGS reagents under contracts with Twist Bioscience and New England Biolabs (both U.S. companies), settled in U.S. dollars, and reflects the dollar-denominated assets and results of its U.S. CLIA lab subsidiaries in its consolidated financial statements. Changes in the KRW/USD exchange rate affect reagent and equipment purchase costs and consolidated translation amounts in opposite directions.

The domestic/overseas revenue split, the scale of dollar-denominated liabilities and foreign currency translation gains/losses, and the specific quantitative impact of the specimen testing fee cut on LabGenomics are not available.

Risk Factors

• The company has a structure of continued losses: an operating loss of 116.3억원 in 2024, a net loss of 643억원 in 2025 (approximately 5.2x wider than the prior year), and an operating loss of 41.78억원 continuing into Q1 2026 (Business Report, Goover Report).
• The 200억원 convertible bonds resolved on 2026-05-12 (convertible into 18.38% of total shares outstanding) carry potential equity dilution once the conversion request period begins after 2027-05-20 (DART).
• The 5:1 reverse stock split resolved on 2026-06-29 requires a special resolution at the extraordinary general meeting on 2026-08-18, and the plan could change if it is not approved (DART).
• Under the Health Insurance Fee Structure Reform Plan announced on 2026-06-25, specimen testing fees are scheduled to be cut starting H2 2026, which is expected to put downward pressure on unit prices for domestic outsourced testing revenue (Ministry of Health and Welfare).
• Regarding the U.S. CLIA lab acquisitions totaling approximately 900억원 in 2023-2024, reporting as of 2025-09 pointed to weak integration performance; while organizational integration and sales strengthening efforts have continued since then, visible results have not yet been confirmed (Sisa Journal e).
• The U.S. reciprocal tariff on Korea (25%, including medical devices) in effect since 2025-04-09 is assessed to have limited impact given LabGenomics' local service structure, but exposure could increase if the share of exported domestically-made diagnostic kits grows in the future (Medipana News).